Help Your Eligible Patients Save on ZIRGAN*

With the Bausch + Lomb Access Program, most eligible patients can save on their ZIRGAN prescriptions.*

This program offers savings up to $35 for eligible commercially insured patients and up to $135 off for eligible uninsured patients.*

Patients can download and activate a Bausch + Lomb Access card by visiting bauschaccessprogram.com.

  • Patients who receive a physical co-pay card in office can activate online at blsavings.com, on the phone by calling
    1-866-693-4880, or by texting BLSAVINGS to 24109
  • Once the card has been downloaded or activated, patients can take it to Walgreens or a participating independent pharmacy to pick up their prescription

*Terms, conditions and limitations apply. See eligibility criteria and terms and conditions at bauschaccessprogram.com.

Message and data rates may apply. Full terms can be viewed at https://bauschaccess.copaysavingsprogram.com/sms-terms.

Accessing ZIRGAN

See if your patients are covered with Bausch + Lomb’s formulary tool.

Check our formulary tool
Interested in ZIRGAN samples?

Requesting samples is quick and easy through the Bausch Sample Vault.

Request samples
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: